Titan Pharmaceuticals, Inc. (NASDAQ:TTNP – Get Free Report)’s share price passed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $6.07 and traded as low as $4.26. Titan Pharmaceuticals shares last traded at $4.30, with a volume of 12,361 shares trading hands.
Wall Street Analysts Forecast Growth
Separately, StockNews.com assumed coverage on Titan Pharmaceuticals in a report on Thursday. They set a “sell” rating on the stock.
Read Our Latest Analysis on TTNP
Titan Pharmaceuticals Stock Down 0.7 %
Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) last released its quarterly earnings results on Thursday, August 15th. The specialty pharmaceutical company reported ($2.29) EPS for the quarter.
About Titan Pharmaceuticals
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
Recommended Stories
- Five stocks we like better than Titan Pharmaceuticals
- Why is the Ex-Dividend Date Significant to Investors?
- Chinese Stocks Cool Off: Time to Buy the Dip in These 2 Stocks?
- How to Invest in Small Cap StocksĀ
- Goldman Sachs Highlights 3 Top Short Squeeze Stocks to Watch
- The Significance of Brokerage Rankings in Stock Selection
- Walmart is Up 56% YTD, Is it Still a Top Consumer Staples Stock?
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.